Find Risperdal Attorneys for Minnesota Claims
Tuesday December 03, 2024
The antipsychotic medication Risperdal (risperidone) has been associated with a heightened risk of gynecomastia, the development of breast tissue in males. Side effects like gynecomastia can be especially troubling for children and adolescent boys already confronting disorders such as schizophrenia, autism, or bipolar disorder. The Risperdal lawyers at our firm are investigating whether the manufacturer unlawfully promoted risperidone for use in Minnesota children and adolescents without regulatory approval by the FDA, and whether victims in Minnesota and elsewhere suffered unnecessary side effects as a result.
If you or a loved one in Minnesota experienced male breast growth while taking Risperdal, you may have important legal rights. Contact our office at (888) 849-5117 or online for an evaluation of your potential Risperdal lawsuit. All consultations are provided at no cost.
Risperdal Illegally Promoted in Minnesota
The United States Food and Drug Administration (FDA) first approved Risperdal for sale in Minnesota and other markets in 1993. At that time, the drug was approved for the short-term treatment of schizophrenia in adults. In 2003, the drug was additionally approved for the short-term treatment of acute manic or mixed episodes in adults.
The first approval of risperidone for use in Minnesota children came in 2006. At that time, the FDA approved Risperdal to treat symptoms of irritability in autistic children and adolescents 5 to 16 years old. In 2007, the FDA further approved Risperdal for the treatment of schizophrenia in adolescents ages 13 to 17, and for the short-term treatment of manic or mixed episodes in bipolar children and adolescents ages 10 to 17.
Evidence now shows that Risperdal's manufacturer may have promoted risperidone to physicians for use in Minnesota children well before the FDA approved such use in 2006. While doctors may prescribe medication for any use they deem appropriate for their patients, drug companies are prohibited by federal law from promoting drugs for any unapproved (or "off-label") uses.
Breast Growth Lawsuits Now Pending
Young male users of Risperdal have reported breast growth that is extreme, uneven, and does not go away without hormone therapy or breast reduction surgery such as mastectomy. These vulnerable Minnesota patients may have suffered unnecessarily as a result of the off-label promotion of Risperdal. Risperdal lawsuits also allege that the manufacturer failed to properly warn Minnesota consumers about the risk of gynecomastia side effects from Risperdal, and that the drug itself may be defectively designed irrespective of the warnings given. Those affected are encouraged to consult a knowledgeable Risperdal lawyer for Minnesota in a timely manner to protect their right to compensation.
Free Case Evaluation
At this time we are no longer accepting claims for the Risperdal litigation.
Visit us at PharmLawyer.com for a list of our current defective drug and medical device lawsuits.